Aurobindo Pharma has reported results for the fourth quarter and year ended March 31, 2016.
The company has posted a rise of 21.02% in its net profit at Rs 407.85 crore for the quarter ended March 31, 2016 as compared to of Rs 337.01 crore for the same quarter in the previous year. Total income of the company has increased by 18.15% at Rs 2415.69 crore for quarter under review as compared to Rs 2044.68 crore for the quarter ended March 31, 2015.
On consolidated basis, the company has registered a jump of 39.39% in its net profit after taxes, minority interest and share of profit/(loss) of associates at Rs 562.85 crore for the quarter ended March 31, 2016 as compared to Rs 403.80 crore for the corresponding quarter in the FY15. Total income of the company increased by 18.89% at Rs 3767.34 crore for quarter under review as compared to Rs 3168.81 crore for the same quarter ended previous year.
For the year ended March 31, 2016, the company has reported a rise of 6.81% in its net profit at Rs 1619.67 crore as compared to Rs 1516.34 crore for the same period in the previous year. Total income of company increased by 13.13% at Rs 9205.47 crore for year under review as compared to Rs 8137.42 crore for the period ended March 31, 2015.
For the year ended March 31, 2016, on the consolidated basis, the company has posted a rise of 25.78% in its net profit after taxes, minority interest and share of profit/(loss) of associates at Rs 1982 crore as compared to Rs 1575.77 crore for the same period in the previous year. Total income of company has increased by 14.45% at Rs 13964.31 crore for year under review as compared to Rs 12201.28 crore for the period ended March 31, 2015.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: